José Fernando Prado Moura, Member of the Oncology Commission at Cremepe, shared a post on LinkedIn:
“Antonio Passaro thanks a lot for this greats days of experience and dephly discussions about EGFR mutated lung cancer at IEO, Istituto Europeo di Oncologia.
It was a pleasure for us knowing you and your team that ‘non teme le sfide’ ”
First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape
